Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorDemirkapu, Mahluga Jafarova
dc.contributor.authorKara, Sonat Pınar
dc.date.accessioned2022-05-11T14:12:46Z
dc.date.available2022-05-11T14:12:46Z
dc.date.issued2021
dc.identifier.issn1128-3602
dc.identifier.urihttps://doi.org/10.26355/eurrev_202111_27264
dc.identifier.urihttps://hdl.handle.net/20.500.11776/5667
dc.description.abstractOBJECTIVE: Concomitant use of drugs not only enhances the therapeutic effect, but may also lead to undesirable interactions. Drug interactions are frequently seen in intensive care patients. In this study, we aimed to determine the frequency and clinical severity of drug interactions in Medical Intensive Care Unit (MICU) patients. PATIENTS AND METHODS: The ordered drugs and blood analysis results of 314 patients aged ?18 years who stayed in the MICU for at least 24 h between January and December 2020 were evaluated. Using the Lexi-Interact online database, clinically significant types of drug interactions, frequently interacting drug/ drug groups, and potential adverse reactions were identified. RESULTS: The average number of drugs in 314 patients was 8.98±5.19. It was determined that polypharmacy was associated with comorbidity and the amount of drug used increased as the number of diagnoses increased. Potential drugdrug interactions were observed in 69.7% of the MICU patients, and it was determined that the amount of interactions increased as the amount of drug used increased. The most common X, D, and C type potential drug-drug interactions, were found between furosemide and salbutamol, enoxaparin and acetylsalicylic acid, ipratropium and potassium chloride, respectively. CONCLUSIONS: Use of frequently interacting drugs in the treatment of critically MICU patients may lead to potential drug-drug interactions and adverse reactions. Daily monitoring and updating of drug therapy can improve patient's quality of life by preventing or reducing potential drugdrug interactions. © 2021 Verduci Editore s.r.l. All rights reserved.en_US
dc.description.sponsorshipThis article was funded by researchers.en_US
dc.language.isoengen_US
dc.publisherVerduci Editore s.r.len_US
dc.identifier.doi10.26355/eurrev_202111_27264
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdverse reactionen_US
dc.subjectClinical pharmacologyen_US
dc.subjectClinically significant drug-drug interactionsen_US
dc.subjectPatient safetyen_US
dc.subjectPharmacovigilanceen_US
dc.titlePotential drug-drug interactions in university hospital medical intensive care unit patients in turkeyen_US
dc.typearticleen_US
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciencesen_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Farmakoloji Ana Bilim Dalıen_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume25en_US
dc.identifier.issue22en_US
dc.identifier.startpage7108en_US
dc.identifier.endpage7114en_US
dc.institutionauthorDemirkapu, Mahluga Jafarova
dc.institutionauthorKara, Sonat Pınar
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid57188876195
dc.authorscopusid57367200900
dc.identifier.scopus2-s2.0-85120867784en_US
dc.identifier.pmid34859876en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster